With the global threat of antimicrobials resistance (MAR) and the spread of COVID-19 becoming global threats, the need for countermeasures to infectious disease is greater than ever.
KYORIN Pharmaceutical Co., Ltd. has a proven track record in providing solutions to medical professionals in infection-related fields, offering information and proposals for resolving issues related to infectious disease and infection control from a multifaceted perspective encompassing prevention, diagnosis and treatment.
* Drug-resistant bacteria that threaten people’s lives around the world
The improper use of antibacterial drugs is leading to a global increase in drug-resistant bacteria, while at the same time the development of new antibacterial drugs is declining, creating a major problem for international society. Estimates are that if this situation continues, the annual global number of deaths from infectious disease caused by drug-resistant bacteria could grow to roughly 10 million people by 2050, from roughly 700,000 in 2013. Measures to counter antimicrobial resistance are therefore being pursued globally.
(Adapted from Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations; The Review on Antimicrobial Resistance, Chaired by Jim O’Neill; December 2014)
GeneSoC® provides rapid, simple, and highly sensitive PCR tests, helping to prevent the spread of infections and promote the appropriate use of antimicrobial drugs.
「GeneSoC®」
From the perspective of responding to various infectious diseases, including COVID-19, and combating antimicrobial resistance (AMR), there is a growing need for enhanced testing equipment that can identify causative microorganisms accurately and quickly.
In fiscal year 2024, KYORIN Pharmaceutical Co., Ltd. launched the lightweight and compact general medical device, the genetic analyzer, “GeneSoC mini 2”. We currently offer a lineup of in vitro diagnostic kits, including “GeneSoC SARS-CoV-2 N2 Detection Kit”, “GeneSoC Influenza Virus A/B Detection Kit”, and “GeneSoC Pertussis Detection Kit”.
Through the development and sale of research reagents and in vitro diagnostics for respiratory and sexually transmitted infections, we contribute to the diagnosis of infectious diseases and the appropriate use of antimicrobial drugs.
Compact Real Time PCR system
GeneSoC® mini 2
Contributing to the treatment of infectious diseases by raising awareness of appropriate procedures
Lasvic
KYORIN Pharmaceutical Co., Ltd. cooperates on surveys and academic projects covering trends in drug-resistant bacteria, working with and supporting infectious disease-related academic seminars and conferences by providing information on the appropriate use of antibacterial drugs to physicians, nurses, and other members of ICTs, ASTs, including clinical technicians. Our efforts include contributing to the treatment of infectious diseases with two types of our proprietary new quinolone antibacterial agent Lasvic tablets and intravenous drip infusion kit.
Contributing infection control at medial institutions
Rubysta and Milton
Because much of transmission of microbes is from environment surfaces to hands, it is important to keep environment surfaces clean in addition to disinfecting hands. KYORIN Pharmaceutical Co., Ltd. is contributing to the control of infections with its lineup of the multipurpose disinfectant cleaner Rubysta and the disinfectant Milton, as infection countermeasure.